SCHEMBL7038347

SCHEMBL7038347

Cc1ccccc1C(=NO)c1ccc(Nc2cnc3ccccc3c2)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.47
MAPK14 Q16539 6/20 0.46
MAPK13 O15264 5/20 0.46
MAPK12 P53778 5/20 0.46
MAPK11 Q15759 5/20 0.46
POLB P06746 2/20 0.45
IGF1R P08069 2/20 0.44
TNF P01375 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NOTUM Q6P988 1/20 0.41
KDM4E B2RXH2 1/20 0.38
MITF O75030 1/20 0.38
XBP1 P17861 1/20 0.38
PAX8 Q06710 1/20 0.38
KLF5 Q13887 1/20 0.38
TMPRSS4 Q9NRS4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7035891 0.85 MAPK13 (0.67) KDRMAPK14MAPK13MAPK12MAPK11
SCHEMBL7032510 0.85 KDR (0.49) KDRMAPK14MAPK13MAPK12MAPK11
SCHEMBL7037510 0.84 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11POLB
SCHEMBL7038381 0.84 NPC1 (0.54) MAPK14MAPK13MAPK12MAPK11POLB
SCHEMBL7037794 0.82 MAPK14 (0.45) MAPK14MAPK13MAPK12MAPK11NPC1
SCHEMBL1907236 0.81 MAPK14 (0.67) MAPK14MAPK13MAPK12MAPK11POLB
SCHEMBL7036523 0.81 MAPK14 (0.51) MAPK14MAPK13MAPK12MAPK11POLB
SCHEMBL1904902 0.81 MAPK14 (0.59) KDRMAPK14MAPK13MAPK12MAPK11
SCHEMBL7035645 0.80 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11POLB
SCHEMBL7038369 0.80 MAPK14 (0.49) KDRMAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US claimed
EP-1289958-A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) Leo Pharma A/S (DK) 2003-03-12 EP disclosed
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US disclosed
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-02-07 US disclosed
WO-2001090074-A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha IL1B, IL1A, NFKBIA KDR 3573/4885MAPK14 625/4885MAPK13 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.